Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Share-based Compensation (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Share-based Compensation data on record, last reported at $4.0 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 94.87% year-over-year to $4.0 million; the TTM value through Sep 2025 reached $15.4 million, up 65.27%, while the annual FY2024 figure was $9.8 million, 32.1% up from the prior year.
  • Share-based Compensation reached $4.0 million in Q3 2025 per CAPR's latest filing, up from $3.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.5 million in Q1 2025 and bottomed at $712299.0 in Q2 2021.
  • Average Share-based Compensation over 5 years is $2.0 million, with a median of $1.7 million recorded in 2023.
  • The widest YoY moves for Share-based Compensation: up 161.62% in 2021, down 1.13% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $780150.0 in 2021, then soared by 47.18% to $1.1 million in 2022, then skyrocketed by 62.14% to $1.9 million in 2023, then rose by 23.31% to $2.3 million in 2024, then skyrocketed by 74.13% to $4.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $4.0 million in Q3 2025, $3.6 million in Q2 2025, and $5.5 million in Q1 2025.